Stockscreener 앱 받기
36.81
1.63%
-0.6288
전일 마감가:
$37.44
열려 있는:
$37.34
하루 거래량:
590.94K
Relative Volume:
0.57
시가총액:
$2.74B
수익:
-
순이익/손실:
$-301.06M
주가수익비율:
-7.5588
EPS:
-4.87
순현금흐름:
$-248.01M
1주 성능:
+0.77%
1개월 성능:
+20.79%
6개월 성능:
-14.31%
1년 성능:
+74.14%
1일 변동 폭
$36.30
$37.55
1주일 범위
$34.29
$38.58
52주 변동 폭
$20.19
$53.92
Springworks Therapeutics Inc Stock (SWTX) Company Profile
명칭
Springworks Therapeutics Inc
전화
203-883-9490
주소
100 WASHINGTON BOULEVARD, STAMFORD, CT
SWTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| SWTX | 36.79 | 2.74B | 0 | -301.06M | -248.01M | -4.87 |
| VRTX | 448.94 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.76 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 597.27 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.44 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.05 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Springworks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-05 | 개시 | Guggenheim | Buy |
| 2022-12-01 | 개시 | BofA Securities | Buy |
| 2021-01-19 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2020-03-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-01-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-04 | 개시 | H.C. Wainwright | Buy |
| 2019-10-08 | 개시 | Cowen | Outperform |
| 2019-10-08 | 개시 | Goldman | Buy |
| 2019-10-08 | 개시 | JP Morgan | Overweight |
| 2019-10-08 | 개시 | Wedbush | Outperform |
모두보기
Springworks Therapeutics Inc 주식(SWTX)의 최신 뉴스
SpringWorks started at outperform by Evercore ahead of FDA decision - MSN
SpringWorks Therapeutics (NASDAQ:SWTX) Now Covered by Evercore ISI - MarketBeat
Does SpringWorks Therapeutics (SWTX) Have the Potential to Rally 92.68% as Wall Street Analysts Expect? - MSN
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark - MSN
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Position Boosted by Victory Capital Management Inc. - MarketBeat
SpringWorks Therapeutics: Q3 Earnings Snapshot - AOL
Equities Analysts Set Expectations for SWTX FY2024 Earnings - Defense World
Wedbush Has Negative Forecast for SWTX FY2024 Earnings - Defense World
When (SWTX) Moves Investors should Listen - Stock Traders Daily
Analyst Estimates: Here's What Brokers Think Of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Report - Yahoo Finance
Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results - Simply Wall St
FY2024 Earnings Forecast for SWTX Issued By HC Wainwright - MarketBeat
Wedbush Has Negative Outlook for SWTX FY2024 Earnings - MarketBeat
SpringWorks Therapeutics Inc (SWTX) Quarterly 10-Q Report - Quartzy
Los Angeles Capital Management LLC Boosts Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
HC Wainwright Issues Pessimistic Forecast for SpringWorks Therapeutics (NASDAQ:SWTX) Stock Price - Defense World
SpringWorks Therapeutics (NASDAQ:SWTX) Releases Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q3 2024 Earnings Call Transcript - Insider Monkey
Principal Financial Group Inc. Has $29.43 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highli - GuruFocus.com
SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap Down on Analyst Downgrade - Defense World
SpringWorks Therapeutics Q3 2024 Results Overview - TipRanks
SpringWorks Therapeutics Inc (SWTX) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
SpringWorks Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - XM
HC Wainwright Cuts SpringWorks Therapeutics (NASDAQ:SWTX) Price Target to $74.00 - MarketBeat
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference - The Manila Times
SpringWorks Therapeutics to Present at Jefferies London Healthcare Conference | SWTX Stock News - StockTitan
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
SpringWorks Therapeutics (SWTX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
SpringWorks Therapeutics’ mirdametinib shows efficacy in neurofibromatosis study - Yahoo Finance
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Bakersfield Californian
SOPHiA GENETICS (NASDAQ:SOPH) vs. SpringWorks Therapeutics (NASDAQ:SWTX) Financial Review - Defense World
Earnings To Watch: SpringWorks Therapeutics Inc (SWTX) Reports Q - GuruFocus.com
SpringWorks Therapeutics Announces Mirdametinib Data to be - GlobeNewswire
SpringWorks' Cancer Drug Shows Breakthrough 62% Response Rate, FDA Fast-Tracks Review | SWTX Stock News - StockTitan
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology - Quantisnow
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating - The Bakersfield Californian
SpringWorks Therapeutics Announces Publication of the - GlobeNewswire
SpringWorks' Mirdametinib Shows Breakthrough 52% Response Rate in NF1-PN Trial | SWTX Stock News - StockTitan
Creative Planning Takes $254,000 Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
SpringWorks Therapeutics (SWTX) Set to Announce Earnings on Tuesday - Defense World
Fiera Capital Corp Lowers Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Earns Outperform Rating from Wedbush - Defense World
Brokerages Set SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Price Target at $68.50 - Defense World
SpringWorks Therapeutics Announces Long-Term Efficacy and - GlobeNewswire
SpringWorks' OGSIVEO Shows 75.8% Tumor Reduction in 4-Year Treatment Data | SWTX Stock News - StockTitan
What's Going On With Rare Diseases-Focused SpringWorks Therapeutics Stock Today? - MSN
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Mirae Asset Global Investments Co. Ltd. Buys 474 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
SpringWorks Therapeutics (SWTX) to Release Earnings on Tuesday - MarketBeat
Springworks Therapeutics Inc (SWTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):